Upcoming FDA decision · November 10, 2026
TAK-771 PDUFA date: FDA decision expected November 10, 2026
48 days to goTAKEDA PHARMACEUTICAL CO LTD (TAK) →
The FDA is expected to decide on TAK-771 from TAKEDA PHARMACEUTICAL CO LTD in Primary Immunodeficiency Diseases (PID) by the PDUFA target action date of November 10, 2026. For eosinophilic esophagitis. NDA filing. Extracted from SEC filing: 6-K
A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.
November 10
Target action date
Phase 3
Stage
Detected
Date confidence
—
FDA designations